Abstract: Stucco-cement compositions with a shortened drying time, lighter weight, high strength and reduced expansion, the compositions comprising expanded perlite and preferably also calcium aluminate cement and/or calcium sulfoaluminate cement, and methods for making and using these compositions, including pourable and/or pumpable floor underlayment slurries and methods for forming high strength underlayment on different substrates.

Abstract: Various cement-containing compositions are disclosed, to be made into forms, and prefabricated building materials produced from cement-containing compositions with insulating properties. Some of the preferred embodiments include expanded polystyrene and an acrylic component to provide enhanced insulating properties, or have a lower density, lighter weight, and increased insulating R-value in comparison with other cement-containing compositions.

Abstract: The present invention provides a system for continuous production of sulfur polymer cement. The system may include a series of high shear mixers, such as twin screw mixers or compounding extruders, to which a sulfur-containing starting material is added at one end, followed by at least one stage at which a sulfur modifier is added. Micro-aggregate may be added at one or more stages. At the discharge end of the continuous system, an extrudate is produced, and a pelletizer may be used to form pellets of the polymerized sulfur and micro-aggregate material. The pelletizer may comprise a flowing cooled water system, e.g., underwater pelletizer. The formed pellets may then go through a dryer system and then to a dry storage collection system.

Abstract: A multilayer ceramic capacitor includes: a ceramic body in which dielectric layers and first and second internal electrodes are alternately stacked; and first and second external electrodes formed on an outer surface of the ceramic body and electrically connected to the first and second internal electrodes, respectively. In a microstructure of the dielectric layer, dielectric grains are divided by a dielectric grain size into sections each having an interval of 50 nm, respectively, a fraction of the dielectric grains in each of the sections within a range of 50 nm to 450 nm is within a range of 0.025 to 0.20, and a thickness of the dielectric layer is 0.8 ?m or less.

Abstract: The present disclosure relates to a method for preparing a silicon nitride ceramic material. The method including: (1) with at least one of silicon powder and silicon nitride powder as original powder and Y2O3 powder and MgO powder as sintering aids, the original powder and the sintering aids are mixed in a protective atmosphere, and the mixture is formed into a green body; (2) the resulting green body is put into a reducing atmosphere and pretreated at 500° C. to 800° C. to obtain a biscuit; and the reducing atmosphere is a hydrogen/nitrogen mixed atmosphere with a hydrogen content not higher than 5%; (3) the resulting biscuit is put into a nitrogen atmosphere and subjected to low-temperature heat treatment at 1600° C. to 1800° C. and high-temperature heat treatment at 1800° C. to 2000° C. in sequence.

Abstract: A method of predicting characteristics of concrete includes inputting data on a cement mixture including cement and an admixture, calculating reactivity of the admixture based on the data, and predicting products of the cement mixture based on the reactivity, and an embodiment further includes predicting characteristics of concrete based on the predicting of the products of the cement mixture based on the reactivity.

Abstract: An article having a coating system configured to inhibit or prevent crystallization of TGO at the operating temperature of the article. An article includes a substrate defining a surface and a coating layer that includes a dopant configured to inhibit crystallization of amorphous silicon dioxide thermally grown oxide on the bond coat at an operating temperature of the article. The dopant includes a glass modifier. By inhibiting or preventing TGO crystallization, the described coating systems may increase a useable life of the component.

Abstract: The combustion system includes a metal additive and a polar outer-sphere electron transferring solvent. The metal additive is solvated in the polar outer-sphere electron transferring solvent. The polar outer-sphere electron transferring solvent may include liquid ammonia, methylamine, and/or hexamethylphosphoramide. The metal additive may include an alkali metal and/or an alkaline earth metal. For instance, the metal additive may include lithium, sodium, aluminum, zirconium, titanium, yttrium, hafnium, and/or magnesium.

Abstract: An explosive emulsion composition of the water-in-oil type, comprising: between 80 wt. % and 95 wt. % of an oxidizer phase in view of the total weight of the emulsion composition, comprising at least 40 wt. % of ammonium nitrate (AN), and at least 5 wt. % of a secondary nitrate salt, in view of the total weight of the oxidizer phase composition, and between 5 wt. % and 20 wt. % of an organic phase in view of the total weight of the emulsion composition, the organic phase comprising: between 12 wt. % and 50 wt. % of one or more emulsifiers, between 50 wt. % and 88 wt. % of a fuel composition, in view of the total weight of the organic phase composition, characterized in that the fuel composition comprises between 20 wt. % and 100 wt. % of a hydrotreated vegetable oil (HVO), in view of the total weight of the fuel composition.

Abstract: A method for synthesis and purification of radiolabeled macroaggregated human serum albumin (MAA) to form a bulk solution injectable to a patient includes: providing a radiometal in a generator, the radiometal being a generator eluate; synthesizing the radiolabeled MAA in a reactor with MAA particles from a commercially available labeling kit for 99mTc and the generator eluate so as to provide synthesized radiolabeled MAA particles; passing the synthesized radiolabeled MAA particles on a syringe filter membrane having a membrane composition, diameter, and pore size for trapping the radiolabeled MAA particles as trapped radiolabeled MAA particles and not retaining impurities from a bulk solution, the impurities including free radioactive metal isotopes, parent radioactive metal breakthrough, and stannous chloride present in the MAA labeling kit for 99mTc; and untrapping the trapped radiolabeled MAA particles from the syringe filter using a saline or buffered solution passing through the syringe filter.

Abstract: A process for dehydration of an ethanol feed stream comprising sending said ethanol feed stream and steam to a radial flow reactor to contact a catalyst under reaction conditions and produce an effluent comprising ethylene. The use of a radial flow reactor eliminates concerns about pressure drops that may occur with conventional fixed bed downflow reactors.

Abstract: A fluidized catalytic conversion method for maximizing the production of propylene includes the steps of: 1) contacting a heavy feedstock oil with a catalytic conversion catalyst having a temperature of 650° C. or higher for reaction; 2) contacting a hydrocarbon oil feedstock having an olefin content of 50 wt % or more with the catalytic conversion catalyst after the reaction of step 1); 3) separating a first catalytic cracking distillate oil and a second catalytic cracking distillate oil from the resulting reaction products; 4) separating an olefin-rich stream from the first catalytic cracking distillate oil; and 5) recycling the olefin-rich stream. The method can effectively improve the yield of propylene and realize an effective utilization of petroleum resources.

Abstract: Processes for producing olefins include passing a hydrocarbon feed to a hydrocarbon cracking unit that cracks the hydrocarbon feed to produce a cracker effluent, passing the cracker effluent to a cracker effluent separation system that separates the cracker effluent to produce at least a cracking C4 effluent including 1-butene, 1,3-butadiene, and isobutene, passing the cracking C4 effluent to an SHIU that contacts the cracking C4 effluent with hydrogen in the presence of a selective hydrogenation catalyst to produce a hydrogenation effluent having a 2-butenes concentration greater than or equal to the sum of the concentrations of 1-butene and isobutene. The processes include passing the hydrogenation effluent to a metathesis unit that contacts the hydrogenation effluent with a metathesis catalyst and a cracking catalyst downstream of the metathesis catalyst to produce a metathesis reaction effluent comprising at least propene.

Abstract: A preparation process of 5-ethylidene-2-norbornene, including: introducing dicyclopentadiene into a dicyclopentadiene decomposition reactor to thermally decompose the dicyclopentadiene; introducing a product of the above step into a cyclopentadiene purification tower; introducing 1,3-butadiene, a solvent, and cyclopentadiene separated from the top of the cyclopentadiene purification tower into a Diels-Alder reactor to react the same; introducing a product of the immediate above step into a 1,3-butadiene removal tower to recover 1,3-butadiene from the top; introducing a mixture at the bottom of the 1,3-butadiene removal tower into a desolvation tower, and recycling a solvent and unreacted raw materials recovered from the top of the desolvation tower to the dicyclopentadiene decomposition reactor; introducing a mixture at the bottom of the desolvation tower into a 5-vinyl-2-norbornene separation tower to separate 5-vinyl-2-norbornene; and introducing the 5-vinyl-2-norbornene into an isomerization reactor to rea

Abstract: A fluoroalkyne compound can be efficiently synthesized from a fluoroalkane compound by a method for producing a fluoroalkyne compound represented by formula (1): R1C?CR2??(1) wherein R1 and R2 are the same or different and each is a fluorine atom or a fluoroalkyl group, the method comprising subjecting a fluoroalkane compound represented by formula (2): R1CHX1CFX2R2??(2) wherein R1 and R2 are as defined above; and X1 is a fluorine atom and X2 is a hydrogen atom, or X1 is a hydrogen atom and X2 is a fluorine atom, to a dehydrofluorination reaction in the presence of an ether solvent, the method satisfying at least one requirement selected from the group consisting of the following: (I) the fluoroalkyl group is a C1-C4 fluoroalkyl group, and (II) the ether solvent is a chain ether compound, and the dehydrofluorination reaction is performed in the presence of the solvent containing a chain ether and a base comprising a hydroxide and/or alkoxide of an alkali metal and/or alkaline earth metal.

Abstract: The present invention relates to a method for decomposing polyfluorocarboxylic acids, characterized in that a mixture containing polyfluorocarboxylic acids, water, and a basic compound is heated.

Abstract: A process for producing methanol from an adjusted make-up gas comprising the steps of adjusting the stoichiometric number of the make-up gas fed to the methanol loop with a first stream of hydrogen recovered from a minor portion of makeup gas separated from the main stream, and a second stream of hydrogen recovered from the loop purge; the process further comprises the step of feeding at least a portion of a tail gas rich in methane to a reforming stage for use as a feedstock to produce the make-up gas.

Abstract: The present invention relates to a process for preparing bisphenol A in the presence of alpha-methylstyrene without poisoning the catalyst system comprising an ion exchange resin catalyst and a sulfur containing cocatalyst. Moreover, the present invention provides a process for preparing polycarbonate.

Abstract: The present invention relates to a process for preparing bisphenol A in the presence of 2-methyl benzofuran without poisoning the catalyst system comprising an ion exchange resin catalyst and a sulfur containing cocatalyst, wherein at least part of the sulfur containing cocatalyst is neither covalently nor ionically bound to the ion exchange resin catalyst. Moreover, the present invention provides a process for preparing polycarbonate.

Abstract: A method for producing isobutyl vinyl ether using isobutyl alcohol as a raw material alcohol, the method including reacting the isobutyl alcohol with acetylene to obtain a mixture containing unreacted isobutyl alcohol and isobutyl vinyl ether, reacting the unreacted isobutyl alcohol and the isobutyl vinyl ether in the mixture in a presence of an acid catalyst to be converted into acetaldehyde diisobutyl acetal, and removing the acetaldehyde diisobutyl acetal by distillation.

Abstract: Systems and methods are provided for ozonolysis of polycyclic aromatic hydrocarbons (PAHs) in a liquid CO2 reaction environment. It has been unexpectedly discovered that oxygen-containing functional groups can be added to PAH substrates while substantially avoiding combustion reactions and while reducing or minimizing formation of energetic intermediates. Because the formation of energetic intermediates is minimal, the ozonolysis can be performed at temperatures near ambient (e.g., between ?10° C. and 50° C.) while still achieving a satisfactory safety profile. In various aspects, ozonolysis can occur while forming a reduced or minimized amount of water, such as forming substantially no water in the reaction environment.

Abstract: A platinum group metal ion-supported catalyst in which platinum group metal ions or platinum group metal complex ions are supported on a non-particulate organic porous ion exchanger, wherein the non-particulate organic porous ion exchanger is formed of a continuous framework phase and a continuous pore phase; has a thickness of a continuous framework of 1 to 100 ?m, an average diameter of continuous pores of 1 to 1000 ?m, and a total pore volume of 0.5 to 50 ml/g; has an ion exchange capacity per weight in a dry state of 1 to 9 mg equivalent/g; and has ion exchange groups wherein the ion exchange groups are uniformly distributed in the organic porous ion exchanger.

Abstract: The present invention discloses a method for preparing an ibuprofen spherical crystal having high bulk density and a product thereof. The method includes: (1) heating ibuprofen until a molten liquid state is reached; and (2) pressurizing the molten liquid state of ibuprofen, dropping the molten liquid state of ibuprofen into a crystallizer filled with water through a liquid distributor for crystallization under stirring conditions until the molten liquid state of ibuprofen is completely dropped, lowering the rotation speed of stirring to allow crystal growing, and finally, subjecting a resulting crystal slurry to post-treatment to obtain the ibuprofen spherical crystal having high bulk density. The ibuprofen spherical crystal has a bulk density of 0.50-0.70 g/mL, a tap density of 0.63-0.89 g/mL, a median particle size of 300-1,000 ?m and an angle of repose of 22-29°.

Abstract: A method for recovering a composition enriched in 3-hydroxypropionic acid from a fermentation broth comprising 3-hydroxypropionic acid and/or salts thereof comprises the steps of: (a) providing the fermentation broth having a pH of from about 2 to about 8 comprising: 3-hydroxypropionic acid and/or salts thereof, (b) acidifying the fermentation broth; (c) reducing the total sulfate ion and phosphate ion (d) distilling the resulting reduced ion aqueous solution and (e) recovering the product.

Abstract: Provided are a method for preparing chiral nitro derivatives using organic chiral catalyst compounds and water as an eco-friendly solvent, and the like. The catalyst is an organic catalyst based on (R,R)-1,2-diphenylethylenediamine (DPEN), and can prepare nitro derivatives having enantioselectivity and diastereoselectivity in excellent yield through a hydrophobic hydration effect. In particular, the preparation method of the present disclosure can stabilize a transition state through an interfacial reaction between the catalyst and water. In addition, indole derivatives can be synthesized using the chiral nitro derivatives prepared according to the present disclosure to be usefully used for the prevention or treatment of brain-nervous system diseases including depression and muscular diseases including cachexia.

Abstract: A method for preparing a diaryl-p-phenylenediamine compound of Formula I comprises the steps of reacting a compound of Formula II and a compound of Formula III in a condensation dehydrogenation reaction in the presence of a solvent, a hydrogen acceptor, a water-carrying agent, and a catalyst; wherein R1, R2 and R3 are independently selected and each is H, a C1-C8 alkyl, a C3-C8 cycloalkyl, a C1-C8 alkoxy, a C3-C8 cycloalkoxy, or phenyl; a and c are independently selected and each is an integer of 0 to 5, and b is an integer of 0 to 4:

Abstract: The present invention relates to crystalline forms of a phenyl carbamate derivative compound and compositions and uses thereof.

Abstract: In various aspects, the present disclosure pertains to systems for forming hydrogels that comprise an iodinated polyamino compound and a reactive multi-arm polymer that comprises a plurality of hydrophilic polymer arms having reactive end groups that are reactive with amino groups of the iodinated polyamino compound. Other aspects of the present disclosure pertain to medical hydrogels that are formed by crosslinking the iodinated polyamino compound and the reactive multi-arm polymer of such systems. Further aspects of the present disclosure pertain to medical procedures that can be performed using such systems. Still other aspects of the present disclosure pertain to methods of making iodinated polyamino compounds.

Abstract: A method for the preparation of the 2-hydroxy-4-methylthiobutyronitrile (HMTBN) or its selenium equivalent (HMSeBN) from hydrocyanic acid and 3-methylthiopropanal (MTP) or the corresponding selenium aldehyde (MSeP) includes the following steps: the molar ratio of the HCN to MTP or to MSeP is adjusted to a value greater than or equal to 1 and the pH is adjusted and maintained at a value greater than or equal to 3.5, to obtain a reaction medium in which the HMTBN or the HMSeBN is formed, then the pH of the reaction medium is lowered to a value less than or equal to 2.5 and the HCN is extracted from the reaction medium, and the HMTBN or the HMSeBN is recovered. The applications of this method are also related.

Abstract: The present application relates to polypeptides which are integrin antagonists. Methods of preparing the integrin antagonists and methods of treating diseases and disorders associated with abnormal levels and/or expression of one or more integrins are also provided.

Abstract: Small molecule potentiatiors to potassium channels (such as Kv7 potentiators—which are also called KCNQ potentiators), compositions including such compounds, and methods of using such compounds for the treatment of Amyotrophic Lateral Sclerosis and other neurological diseases caused by changes in motor neuron excitability, including, but not limited to, primary lateral sclerosis, pseudobulbar palsy, progressive bulbar palsy, progressive muscular atrophy and epilepsy.

Abstract: Synthetic ?v?6 integrin ligands of Formula I having serum stability and affinity for integrin ?v?6, which is a receptor expressed in a variety of cell types, are described. The described ligands are useful for delivering cargo molecules, such as RNAi agents or other oligonucleotide-based compounds, to cells that express integrin ?v?6, and thereby facilitating the uptake of the cargo molecules into these cells. Compositions that include ?v?6 integrin ligands and methods of use are also described.

Abstract: The present disclosure relates generally to compounds and methods for inhibiting the enzymatic activity of lysine demethylase 4 (KDM4) and treating cancer. Provided herein are substituted pyridine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibiting lysine demethylase 4. Furthermore, the subject compounds and compositions are useful for the treatment of breast cancer and the like.

Abstract: The present application provides compounds that modulate the activity of one or more eIF2? kinases. Pharmaceutical compositions and methods of treating diseases related to one or more eIF2? kinases are also provided.

Abstract: The invention relates to the technical field of synthesis of a heterocyclic compound, and particularly discloses a method for preparing 2,4-diaminopyrimidine oxide. The method includes the steps of: cyclizing 3-oxopropionitrile with guanidine under an oxidizing condition to obtain 2,4-diaminopyrimidine oxide, wherein the 3-oxopropionitrile is obtained by oxidizing 3-hydroxypropionitrile, which is a cheap and easily available pharmaceutical chemical, as a raw material. The method of the present invention is green and mild, realizing the synthesis of Aminexil from a simple, cheap and easily available raw material.

Abstract: A Janus G-C base as building block for a triazine based self-assembly of formula (I), a process for the preparation, and its application in developing supramolecular polymers, peptide nucleic acids (PNAs) and smart polymers thereof. A triazine based self-assembly of formula (I): wherein, ‘R’ is selected from the group comprising of linear or branched unsubstituted and substituted C1-C7 alkyl, unsubstituted and substituted aryl, unsubstituted and substituted natural amino acids which may be protected, linear or branched unsubstituted and substituted C1-C7 alcohols, or linear or branched unsubstituted and substituted C1-C7 amines.

Abstract: Provided is a crystal of a specific oxazole compound that has specific inhibitory activity against PDE4, and that shows excellent stability. Specifically, provided is a crystal of an oxazole compound represented by formula (5) wherein the crystal has peaks at diffraction angles)2?(°) of 9.6±0.2, 19.1±0.2, and 21.2±0.2 in an X-ray powder diffraction pattern measured using CuK? characteristic X-rays.

Abstract: The invention relates to a process for preparing 1,2?-benzisothiazoline-3-one according to formula (I), comprising the following steps: (a) reacting a 2-halogenbenzonitrile compound of general formula (II) with a reaction mixture, containing: (i) alkaline sulphide and/or alkaline hydrogen sulphide and (ii) an alkyl halide compound, represented by general formula (III): R1X (III) for producing an intermediate product of general formula (IV), and (b) reacting the intermediate product of general formula (V) obtained in step (a) with a halogenating agent or an oxidant and subsequent reaction of the 2-(alkylsulfoxy)benzonitrile with an acid to form 1,2-benzisothiazoline-3-one as well as a halide compound of general formula (V) R1X (V).

Abstract: A system and method for preparing epoxy chloropropane is provided in that by coupling three stages of high gravity reactors, the product epoxy chloropropane and water vapor are distilled from a reaction system in form of an azeotrope by adopting a water vapor steam stripping method. Further, by combining the azeotrope with the multiples stages of high gravity reactors, the gas phase mass transfer and the liquid phase mass transfer of the azeotrope are improved aiming at the features of the azeotrope in the reaction system, thus making the overall conversion rate higher. In addition, by combining steam stripping and high gravity, dichloropropanol and alkali solution are rapidly mixed for mass transfer, and the product epoxy chloropropane is rapidly distilled from the reaction system in the form of the azeotrope, such that the reaction proceeds continuously towards the direction of producing epoxy chloropropane, thus significantly improving the conversion rate.

Abstract: The present invention provides a compound having an mPGES-1 inhibitory activity and useful for the prophylaxis or treatment of pain, rheumatism, osteoarthritis, fever, Alzheimer's disease, multiple sclerosis, arteriosclerosis, glaucoma, ocular hypertension, ischemic retinal disease, systemic scleroderma and/or cancer including colorectal cancer. The present invention relates to a compound of formula [I-a], [I-b] or [I-c] or a pharmaceutically acceptable salt thereof: wherein each symbol is as defined in the specification.

Abstract: The present application relates to a novel benzoazepine compound, comprising a pharmaceutically acceptable salt thereof. The present application also provides a pharmaceutical composition comprising the compound and a pharmaceutically acceptable salt thereof. The present application relates to use of the compound and the composition in the prevention or treatment of diseases related to arginine vasopressin V1a receptor, arginine vasopressin V1b receptor, arginine vasopressin V2 receptor, sympathetic nervous system or renin-angiotensin-aldosterone system. The present application also provides a method for preventing and/or treating arginine vasopressin-related diseases.

Abstract: Disclosed are compounds of Formula (I) or salts thereof, wherein R1, R2, R3, R4, and R5 are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

Abstract: The present disclosure relates to bifunctional compounds, which find utility as modulators of estrogen receptor (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end at least one of a Von Hippel-Lindau ligand, a cereblon ligand, inhibitors of apoptosis proteins ligand, mouse double-minute homolog 2 ligand, or a combination thereof, which binds to the respective E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

Abstract: The present invention relates to compounds that are antagonists of the orexin-1 receptor. The compounds have the structural formula (I) defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or disorders associated with orexin-1 receptor activity.

Abstract: The present invention provides compounds useful for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.

Abstract: The present invention relates to compounds of Formula (I) that are inhibitors of c-ABL. The invention also relates to pharmaceutical compositions comprising those compounds, and to their use in the treatment or prevention of medical conditions in which inhibition of c-ABL is beneficial. Such medical conditions include neurodegenerative diseases and cancer.

Abstract: This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.

Abstract: Disclosed are heteroaromatic carboxamides of formula (I), wherein Y, R, and Ar are as defined herein, and pharmaceutically acceptable salts thereof. Also disclosed are the use of the compounds of formula (i) for the treatment of diseases which can be influenced by the inhibition of plasma kallikrein.

Abstract: The invention relates to solid forms of (1R,3S)-3-[3-({[3-(methoxymethyl)-1-methyl-1H-pyrazol-5-yl]carbonyl}amino)-1H-pyrazol-5-yl]cyclopentyl propan-2-ylcarbamate, to pharmaceutical compositions comprising such solid forms, and to use of such solid forms and pharmaceutical compositions for the treatment of cancer.

Abstract: A heterocyclic compound represented by Formula 1 and an organic light-emitting device the heterocyclic compound represented by Formula 1: wherein, in Formula 1, Cz1 is a group represented by Formula 1A, Het1 is a group represented by Formula 1B, wherein, R1 to R10, R20, R30, R40, R50, and b10 to b50 are each independently the same as described in the detailed description of the specification.